iSpecimen Inc. Files 8-K Report

Ticker: ISPC · Form: 8-K · Filed: Dec 1, 2025 · CIK: 1558569

Sentiment: neutral

Topics: 8-k, filing

TL;DR

iSpecimen filed an 8-K, but the key details are buried. Need to dig deeper.

AI Summary

On November 28, 2025, iSpecimen Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific financial transactions or material events were detailed in the provided excerpt.

Why It Matters

This filing serves as a notification to the SEC and investors about significant corporate events. The lack of specific details in this excerpt means further review is needed to understand the nature of the "Other Events."

Risk Assessment

Risk Level: low — The filing is a standard 8-K notification without immediate disclosed financial impact or significant operational changes.

Key Players & Entities

FAQ

What specific "Other Events" are being reported by iSpecimen Inc. in this 8-K filing?

The provided excerpt does not detail the specific "Other Events"; it only indicates this as the item information category.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on November 28, 2025.

What is the principal executive office address for iSpecimen Inc.?

The principal executive office is located at 8 Cabot Road, Suite 1800, Woburn, MA 01801.

Under which section of the Securities Exchange Act is this Current Report filed?

This Current Report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

What is the SIC code for iSpecimen Inc.?

The Standard Industrial Classification (SIC) code for iSpecimen Inc. is 8731, which falls under SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH.

Filing Stats: 498 words · 2 min read · ~2 pages · Grade level 13 · Accepted 2025-12-01 16:05:28

Key Financial Figures

Filing Documents

01. Other Events

Item 8.01. Other Events. On November 28, 2025, iSpecimen Inc. (the "Company") received a letter from the Nasdaq Listing Qualifications Staff (the "Staff") notifying the Company that the Staff has determined the Company now complies with the continued listing requirements under Nasdaq Listing Rules 5550(b)(1), 5550(b)(2), and 5550(b)(3). As previously disclosed in the Company's Current Report on Form 8-K filed on June 5, 2025, the Staff notified the Company on June 4, 2025 that the Company did not comply with the minimum stockholders' equity, market value of listed securities, or net income requirements for continued listing on the Nasdaq Capital Market. Based on the Company's Quarterly Report on Form 10-Q for the period ended September 30, 2025, which reported stockholders' equity of $3,072,711, the Staff has determined that the Company has regained compliance with the applicable continued listing criteria and that the matter is now closed. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 1, 2025 iSPECIMEN INC. By: /s/ Katharyn Field Name: Katharyn Field Title: Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing